Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers November 19, 2018
Pharmacy Choice - Pharmaceutical News - PCI Synthesis Submits Patent for Synthesizing Azelaic Acid - November 19, 2018

Pharmacy News Article

 1/30/18 - PCI Synthesis Submits Patent for Synthesizing Azelaic Acid

NEWBURYPORT, Mass., Jan. 30, 2018 (GLOBE NEWSWIRE) PCI Synthesis, Inc. (www.pcisynthesis.com), a pharmaceutical manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products, submitted a patent filing with the U.S. Patent and Trademark Office (USPTO) for a patent that covers an innovative process to synthesize Azelaic Acid as a drug substance.

Azelaic Acid is used for producing industrial products including polyesters, plasticizers and lubricants and is a component in skin-care products but a large-scale synthesis for drug substance production remains challenging. PCI Synthesis began researching new synthetic processes because it recognized a need for a viable, cost-effective, efficient scale-up process for manufacturing high purity azelaic acid under cGMP conditions for use as an active pharmaceutical ingredient (API).

Historically, Azelaic Acid was an API derived from an animal-based raw material and not well controlled from a GMP standpoint, said Ed Price, President of PCI Synthesis. Current material would not be approvable under the current paradigm of the FDA's approval process. We have developed a novel multi-step, synthetic route that is manufactured completely under cGMP. Therefore, our manufacturing process and analytical package meet all the latest FDA requirements for approval as a drug substance for an ANDA.

About PCI Synthesis
PCI Synthesis is a Pharmaceutical Development CMO (Contract Manufacturing Organization) based in Newburyport, MA and is the largest small molecule drug substance manufacturer in the New England area. PCI is also a commercial manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products for the medical device industry. As a contract manufacturing organization (CMO), PCI provides emerging and mid-sized pharmaceutical companies access to the expertise needed to develop and manufacture complex small molecules. To learn more about PCI Synthesis, its proprietary NCE development activities and process R&D capabilities please visit www.pcisynthesis.com.

Contact:
Linda Pendergast-Savage
Birnbach Communications
508-224-7905
lpendergastsavage@birnbachcom.com


Primary Logo

Source: PCI Synthesis


2018 GlobeNewswire, Inc.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Nov 19: ADHD in Children & Adults: Etiology, Pathology, Pharmacotherapy
Last Chance
Nov 20: Acne Vulgaris: Comprehensive Pharmaceutical Care
Nov 26: COPD Update for Pharmacy Professionals
Nov 27: Management of Bipolar Disorder
Nov 28: A Primer to Paleo
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415